Lung Cancer

pancreatic cancer spread to liver life expectancy :: Article Creator New Study Reveals Targetable Mechanism In Pancreatic Cancer Metastasis Register for free to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. A research paper published today (14 February 2024) in Nature Cancer details new insights into the role of efferocytosis – the burying of dead cells – in pancreatic cancer that spreads to the liver. Liver metastasis occurs in 40–50% of people with pancreatic ductal adenosarcoma (PDAC), and there are currently no effective therapies to cure pancreatic cancer patients that have liver metastasis. Led by University of Liverpool's Professor Michael Schmid and colleagues, this study found PDAC metastases to show high levels of immunosuppressive macrophages, a type of white blood ...

treatment for stage 4 small cell lung cancer :: Article Creator What To Know About Your Non-Small Cell Lung Cancer Prognosis Doctors treat non-small cell lung cancer (NSCLC) with surgery, chemotherapy, and other medical treatments. Typically, an earlier diagnosis leads to a better outlook. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC grows and spreads less aggressively than small-cell lung cancer. This means that doctors can treat it successfully with surgery, chemotherapy, and other medical treatments. Your prognosis will vary, but the earlier a diagnosis is made, the better the outlook. Smoking is the leading cause of NSCLC and other types of lung cancer. Other risk factors include: exposure to asbestos air and water pollutants secondhand smoke The prognosis for NSCLC depends on several factors. The most important factor is the stage of the disease. The 5-year survival rate is the p...

stage iv lung cancer treatment options :: Article Creator Black Men With Advanced Prostate Cancer Are Less Likely To Get The Most Effective Therapies About 1 in 8 men will be diagnosed with prostate cancer in his lifetime. [1] Although prostate cancer is the second leading cause of cancer death in men, behind only lung cancer, the average patient with prostate cancer will not die from the disease. [1] Recent advances in treatment, notably the new hormone therapy agents enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa), have extended the lives of people with advanced prostate cancer. [2] But for certain patients, the statistics are not quite as rosy. Black men are 1.5 times as likely as white men to be diagnosed with prostate cancer in the United States, and advanced prostate cancer is 2.4 times more lethal in Black men than in white men. [3] Could differences in the use of these novel hormonal therapies play a role in...

hematologic cancer :: Article Creator Obesity Linked To Acute Kidney Injury After HDMTX For Hematologic Cancer Some patients with hematologic cancer and obesity are at higher risk of acute kidney injury (AKI) after receiving high-dose methotrexate (HDMTX) in the outpatient setting, suggesting a differential drug clearance and the need for guidelines specific to obese patients. These results were published in Hematology, Transfusion and Cell Therapy HDMTX (500 mg/m2 or higher) is a key part of chemotherapy regimens for the treatment of hematologic cancers; however, AKI is a major drug-induced toxicity that can result in critical organ damage and death when not detected early and treated.  Therefore, HDMTX is administered in the hospital allowing for postadministration monitoring. But in resource-poor areas, it is administered in the outpatient clinic without drug monitoring.  This retrospective study of 302 patients was conducted to review ...

chronic myeloid leukemia treatment :: Article Creator In Chronic Myeloid Leukemia, Are Patients Setting The Right Course For Themselves? Effective therapies have led to improved survival for individuals with chronic myeloid leukemia (CML). However, treatment is generally lifelong, and nonadherence is common, which decreases the likelihood of achieving an optimal response to therapy. Patients who intentionally stop their therapy say they have a higher symptom severity than patients whose reasons for nonadherence are unintentional, such as in cases where they can't afford their medication. The Bottom Line A new study enrolled 94 patients with CML and asked them to self-report, via online questionnaires, their adherence to therapy. The vast majority of patients (92.5%) reported optimal adherence, defined as taking at least 90% of their prescribed CML medication during the 6-month study period. Both patients and physicians found the data-ga...

follicular stage :: Article Creator T Follicular Helper Cells And Associated Cytokines For B Cell Modulation The T follicular helper (Tfh) cells are a dedicated subset of CD4+ T cells that are vital for the affinity maturation, survival, and class switch recombination of B cells. They promote successful B-cell antibody-mediated immune responses. The dysregulation of Tfh cells is linked to chronic graft-versus-host-disease and autoimmune disorder systemic sclerosis. These cells also have vital roles to play in cancer, allergies, viral infections, and asthma. There is an increasing interest in the potential to employ these cells to improve vaccination and therapeutic strategies. Many prominent cytokines positively or negatively regulate Tfh cell differentiation and development. Cytokines IL-6, IL-27, IL-21, and TGF-β1 partner with IL-23 and IL-12 to initiate the differentiation of naive T cells. Consequently, there is an increase in Bcl-6 and up...